Citadel Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-598,197
| Closed | -$23.8M | – | 13809 |
|
|
2026
Q1 | $23.8M | Buy |
598,197
+78,235
| +15% | +$2M | ﹤0.01% | 2123 |
|
|
2025
Q4 | $13M | Buy |
519,962
+382,761
| +279% | +$9.69M | ﹤0.01% | 2894 |
|
|
2025
Q3 | $3.33M | Buy |
+137,201
| New | +$2.44M | ﹤0.01% | 5122 |
|
|
2025
Q2 | – | Sell |
-706,331
| Closed | -$8.95M | – | 12833 |
|
|
2025
Q1 | $10.2M | Buy |
706,331
+81,015
| +13% | +$1.33M | ﹤0.01% | 2833 |
|
|
2024
Q4 | $10.5M | Buy |
625,316
+37,798
| +6% | +$626K | ﹤0.01% | 2928 |
|
|
2024
Q3 | $9.39M | Buy |
587,518
+549,242
| +1,435% | +$6.73M | ﹤0.01% | 2995 |
|
|
2024
Q2 | $346K | Sell |
38,276
-8,692
| -19% | -$82.4K | ﹤0.01% | 8862 |
|
|
2024
Q1 | $531K | Sell |
46,968
-53,836
| -53% | -$510K | ﹤0.01% | 8263 |
|
|
2023
Q4 | $802K | Buy |
100,804
+97,785
| +3,239% | +$656K | ﹤0.01% | 7124 |
|
|
2023
Q3 | $19.5K | Sell |
3,019
-1,086
| -26% | -$7.43K | ﹤0.01% | 12645 |
|
|
2023
Q2 | $25.4K | Buy |
+4,105
| New | +$19.5K | ﹤0.01% | 12526 |
|
|
2023
Q1 | – | Sell |
-72,307
| Closed | -$224K | – | 14806 |
|
|
2022
Q4 | $224K | Sell |
72,307
-153,061
| -68% | -$567K | ﹤0.01% | 9913 |
|
|
2022
Q3 | $906K | Sell |
225,368
-65,215
| -22% | -$298K | ﹤0.01% | 7207 |
|
|
2022
Q2 | $1.42M | Sell |
290,583
-13,843
| -5% | -$88.6K | ﹤0.01% | 6246 |
|
|
2022
Q1 | $2.73M | Sell |
304,426
-35,639
| -10% | -$325K | ﹤0.01% | 5399 |
|
|
2021
Q4 | $3.83M | Sell |
340,065
-9,483
| -3% | -$128K | ﹤0.01% | 4844 |
|
|
2021
Q3 | $5.84M | Sell |
349,548
-106,685
| -23% | -$2.21M | ﹤0.01% | 4015 |
|
|
2021
Q2 | $10.1M | Buy |
+456,233
| New | +$10.7M | ﹤0.01% | 3044 |
|
Citadel Advisors's CNTA Position: Q2 2026 in Review
Citadel Advisors sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 598,197 shares — an estimated $23.8M sold.
Citadel Advisors first reported a position in CNTA in Q2 2021 and held it in 18 quarters. The position peaked at $23.8M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.
- Citadel Advisors reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Citadel Advisors sold 598,197 Centessa Pharmaceuticals shares in Q2 2026, an estimated $23.8M.
- Citadel Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and held it in 18 quarters.
- Citadel Advisors's Centessa Pharmaceuticals position peaked at $23.8M in Q1 2026.
- 0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.
Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.